Although several target therapies have been applied for ovarian cancer, including poly (ADP-ribose) polymerase (PARP) inhibitors and vascular endothelial growth factor (VEGF) inhibitors, a selectable therapeutic approach for relapse or treatment resistance remains limited [3]. Here, VEGFA is linked to ovarian cancer.